|Articles|February 15, 2003
- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Outsourcing Outlook: Contract Services' Crystal Ball
Author(s)Jim Miller
by Jim Miller, Bio/Pharmaceutical Outsourcing Report Developments in 2002 such as acquisitions, excess manufacturing capacity, and less funding for biotechnology will continue to affect the industry long into the new year.
Advertisement
Articles in this issue
almost 23 years ago
Becoming a Partner of Choice and Evaluating Prospective Alliancesalmost 23 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counseloralmost 23 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechalmost 23 years ago
Survival Strategies: Keeping Tabs on Trainingalmost 23 years ago
Biotech World: Contract Manufacturing: Diversity in the European Marketplacealmost 2023 years ago
Virus Inactivation in the 1990s ? and into the 21st Century: Part 5: DisinfectionNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
2
Implementing Automation and Flexible Design for Allogeneic Manufacturing
3
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
4
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
5
